HUMA Humacyte, Inc.

NASDAQ
$0.56

Humacyte, Inc. (HUMA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bullish Insiders bought more than they sold over this window — uncommon at any size.
Cluster activity 1 buyer in the last 30 days 1 buyer in the last 90 days 0 sellers in the last 90 days
Insiders buying
3
5 transactions
Insiders selling
2
2 transactions
Purchases
$90.2K
117,818 shares
Sales
$82.3K
91,774 shares
Net activity
$7.9K
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $82.3K 2 transactions · 91,774 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $41.1K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 14, 2026 , by Jones Keith Anthony .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Jones Keith Anthony Director Buy 10,000 $0.56 $5.6K 50,000
Jones Keith Anthony Director Buy 10,000 $0.69 $6.9K 40,000
Jones Keith Anthony Director Buy 30,000 $0.59 $17.8K 30,000
Sebelius Kathleen Director Buy 56,818 $0.88 $50.0K 148,025
Sander Dale A. CFO and Chief Corp. Dev. Off Sell 10b5-1 45,887 $0.90 $41.1K 267,213 −14.7% of holding
Parikh Shamik J Chief Medical Officer Sell 10b5-1 45,887 $0.90 $41.1K 272,713 −14.4% of holding
Constantino Michael T. Director Buy 11,000 $0.89 $9.8K 43,950

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.